BCM

Houston, TX, United States
Houston, TX, United States
SEARCH FILTERS
Time filter
Source Type

News Article | March 1, 2017
Site: co.newswire.com

BCM One, a leading technology solutions provider, announced today that TMC, a global, integrated media company, has recently named Sophia™, BCM One’s Telecom Expense Optimization tool, as a recipient of a 2017 INTERNET TELEPHONY Product of the Year Award. These awards recognize the most innovative and highest quality IP communications brought to market, or updated, in the past year. Sophia, BCM One’s proprietary tool, provides corporate telecom infrastructures with the capabilities to manage technology spend more efficiently; saving companies significant money across their technology spend.  BCM One’s Sophia tool takes telecom expense management one step further by creating optimization opportunities for businesses including their cloud and mobile usage.  Sophia has helped businesses realize telecom savings of up to 20% of their annual spend within the first year.  “We are very proud of the evolution of our Sophia tool since its rebirth three years ago, and take pride in receiving industry recognition for our solution,” stated Corinne Kerner, Vice President of Technology Optimization Group at BCM One and former professional forensic accountant. “It gives me great pleasure to recognize BCM One with a Product of the Year Award for 2017. I have always been impressed with their commitment to excellence and innovation,” said Rich Tehrani, CEO, TMC. “In the opinion of our distinguished judges, Sophia has proven to be among the best IP communications solutions available on the market. I look forward to continued innovation from BCM One.” The winners of the 2017 INTERNET TELEPHONY Product of the Year are featured in the current issue of  INTERNET TELEPHONY magazine. Founded and headquartered in New York City in 1992, BCM One provides a single source for truly integrated technology solutions that help advance a company's business objectives. Through partnerships with over 50 leading technology suppliers, BCM One offers managed solutions for organizations including unified communications, cloud solutions, telecom expense optimization and connectivity solutions. Companies engage with BCM One for the planning, network design, deployment and/or management of their technology solutions. For more information about BCM One, visit www.bcmone.com and follow us on Twitter and LinkedIn. INTERNET TELEPHONY has been the IP Communications Authority since 1998™. Beginning with the first issue, INTERNET TELEPHONY magazine has been providing unbiased views of the complicated converged communications space.  For more information, please visit www.itmag.com. Global buyers rely on TMC’s content-driven marketplaces to make purchase decisions and navigate markets. This presents branding, thought leadership and lead generation opportunities for vendors/sellers.


News Article | May 29, 2017
Site: www.prnewswire.com

Group revenues for the first quarter in 2017 totaled NIS 1.5 billion compared with NIS 1.3 billion in the same period last year. The reason for the higher level of revenue in the current quarter was the increased E&P activities and contribution of Delek Israel. Group operating profit in the first quarter of 2017 totaled NIS 338 million, compared with NIS 277 million as reported in the same period last year. The increase was mainly due to higher sales of natural gas from the Tamar reservoir. Net income for the first quarter of 2017 totaled NIS 220 million compared with NIS 85 million in the first quarter of 2016. The E&P segment contributed a record of NIS 127 million to the Company's net income in the first quarter. Cash balance at the Delek Group as of May 28, 2017, stood at NIS 1.5 billion, including unutilized credit lines. It is noted that on February 22, 2017, Delek Group completed a successful debentures issuance through an expansion of Series B31, contributing NIS 1.0 billion to the balance sheet. Mr. Asaf Bartfeld, President and CEO of Delek Group, commented, "We have started off 2017 with strong financial results, and during the quarter we successfully completed a series of important strategic steps. Having acquired control of Ithaca, we intend to continue to strengthen the Group's international presence as part of our strategy to focus on the energy sector and become a key player in global markets". Tamar Project, 11 TCF natural gas discoveries (Tamar and Tamar SW). Tamar produced 2.4 BCM (~0.93 Bcf/d) of natural gas in the first quarter of 2017, an increase of 9% compared with 2.2 BCM (~0.85 Bcf/d) in the same period last year. In addition, Tamar sold 114 thousand barrels of condensate in the quarter, compared with 104 thousand barrels in the same period last year. Delek Group's (WI 17.68% of Tamar) average production for the quarter amounted to ~30.7k Boe/d. Tamar-8 development and production well: The drilling that began in October 2016 was completed in April 2017, including the completion of its connection to the production system. Tamar Sale Process: As per the Natural Gas Outline Plan, with regard to the Tamar sale to a third party, Delek Group's partnership, Delek Drilling (the new merged entity), announced that it intends to set up a Special Purpose Corporation. Through this, it will sell up to 10% of its rights in the Tamar and Dalit fields (out of 100% WI), located in the areas of leases I/12 Tamar and I/13 Dalit, respectively. This is subject to obtaining all the authorizations required in law as well as the various approvals and permits, and suitable market conditions. There can be no certainty that these conditions will all occur. According to the sale plan, the Special Purpose Corporation will offer securities to the public (equity and debentures) that will be registered for trading on the Tel Aviv Stock Exchange, and the Special Purpose Corporation will use the funds raised from the offering to purchase the rights in the fields that are sold by the Partnership. The profits from the above-mentioned sale, and profit from future sales of all the Partnership's holdings in the fields, are expected to be mainly used by the Partnership to distribute profits (including the distribution of advance tax payments), and for early repayment of debentures. In parallel to advancing the offering, the Partnership is continuing to assess various alternatives for the sale of the balance of its holdings in the fields. Leviathan, a 22 TCF natural gas discovery. On February 20, 2017, the Delek Group partnership signed a USD 1.75 billion limited recourse project financing agreement with a banking consortium for the development of Leviathan.  On February 23, 2017, an FID for Phase 1A of the development plan for the Leviathan Reservoir was sanctioned, with capacity of 12 BCM per year (~1.2 Bcf/d), and budget of USD 3.75 billion (at 100% WI), targeting first gas by the end of 2019. In April 2017, the Atwood Advantage drilling rig moved from Tamar to Leviathan. Drilling began at the Leviathan-7 development and production well, and reached the planned depth of 2,900 meters below sea level. The Atwood Advantage rig subsequently moved to Leviathan-5 and is expected to drill to a final depth of 5,200 meters below sea level. Finally, the rig will return to Leviathan-7 well to drill further to 5,100 meters below sea level. Financing Highlights: On May 12, 2017, all of the preconditions enabling initial withdrawal under the financing agreement were fulfilled. The Partnerships subsequently withdrew the first tranche. These first funds shall be used, inter alia, for payment to the operator, as well as for the costs of the financing. Delek Group's Gas Partnerships' Merger. On May 17, 2017, all of the preconditions and necessary approvals were obtained, and the gas partnerships' subsidiaries were successfully merged, enabling a simpler structure for Delek Group. Avner ceased trading on May 18, 2017, and on May 21, 2017, Delek Drilling began trading as the new merged entity under the same name, Delek Drilling. East Mediterranean E&P Summary. Net income from the sector for the first quarter of 2017 was NIS 119 million, an increase compared to a net income of NIS 101 million last year. The growth was mainly due to the increase in the quantities of natural gas and condensate sold from the Tamar project in the quarter. Delek Group's strategy is to focus on the development of its core assets in the Eastern Mediterranean E&P and expand its activities in global E&P markets, with the intention of becoming a key international player in the energy industry with operational capabilities. Ithaca Energy, Inc: On March 14, 2017, Delek Group offered to buy the remainder of all Ithaca's share capital not already held (80%), at a price of CAD 1.95 per share, following an agreement signed between the Group and Ithaca for issuing a friendly takeover offer. The offer was accepted by the holders of 318,833,909 ordinary shares and the Company bought these shares for a total consideration of CAD 622 million  (NIS 1,710 million). Following this purchase, Delek Group held 500,699,334 ordinary shares in Ithaca, accounting for 94.2% of its ordinary share capital. On May 12, 2017, Delek Group announced that it plans to perform a forced purchase of Ithaca's remaining ordinary shares not held by the Company, at the offer price (CAD 1.95 per share) for a total consideration of CAD 48 million (NIS 130 million). The forced purchase is expected to be completed by the end of June 2017, and Ithaca's shares will be delisted from the Toronto stock exchange and the AIM exchange in London. As of the end of the quarter, Delek Group held 19.7% of the share capital of Ithaca Energy. For the first quarter of 2017, Ithaca's results are presented based on the equity method and contributed NIS 8 million to the Company's income statement. By the end of the second quarter of 2017, the Group is expected to hold 100% of Ithaca, and its results will be fully consolidated into Delek Group's income statement. Due to this purchase, the Group is expected to recognise a profit of NIS 150 million. Operational Highlights: The start-up of the Great Stella Area commenced production in mid-February 2017, producing at constrained rates to minimise gas flaring until processing systems are fully available. Ithaca's average full year 2017 production is anticipated to be in the range of 18,000 to 19,000 Boep/d, reflecting the expected schedule for the step-up in Stella production rates. Ithaca brings Delek Group significant international operational capabilities and firmly establishes the Company's operational arm. Together with Ithaca, Delek Group significantly increases its expected production for 2017 is indicated in the table below; Delek – the Israel Fuel Company Ltd. (fully held by Delek Group); net income for the quarter amounted to NIS 20 million compared with a net income of NIS 4 million in the same period in 2016. The increase was primarily due to a global increase in distillate prices and greater sales volumes. On August 21, 2016, the Group entered into a binding agreement with Yango Investments for the sale of all the Company's holdings (52.3%) in Phoenix Holdings Ltd. On February 16, 2017, the parties signed an amendment to the agreement, extending the period for meeting the stipulated pre-conditions until March 31, 2017. On April 5, 2017, the parties signed an amendment to the agreement, increasing the consideration to NIS 2,152 million. The deadline for completion has been set for June 4, 2017. After this date, each of the parties may inform the other party of its cancellation. On May 1, 2017, Yango informed the Company that it has signed an agreement for the acquisition of shares and cooperation with a company controlled by Yonel Cohen. Yango is expected to hold 50.1% of the share capital in The Phoenix at the end of the process and Yonel will hold 4% of the controlling shares. On May 28, 2017, the Board of Directors of Delek Group declared a cash dividend distribution for the first quarter of 2017 in the amount of approximately NIS 200 million (or NIS 16.6895 per share) to shareholders. The ex-date is on June 13, 2017 and the dividend will be paid on June 27, 2017. The Company will be hosting a conference call in English on Monday, May 29, 2017 at 3.30 PM (Israel Time), 8:30 AM (ET), 1:30 PM (UK). Management will also be available to answer investor questions. To participate, please call one of the following teleconferencing numbers: From the USA on:   1-888-668-9141 Delek Group is an independent E&P and the pioneering visionary behind the development of the East Med. With eight consecutive finds in the Levant Basin, Delek is leading the region's development into a major natural gas export hub. In addition, Delek has embarked on an international expansion with a focus on high-potential opportunities in the North Sea and North America. Delek Group is one of Israel's largest and most prominent companies with a consistent track record of growth. Its shares are traded on the Tel Aviv Stock Exchange (TASE: DLEKG) and are part of the TA 35 Index. For more information on Delek Group please visit www.delek-Group.com or email: investor@delek-Group.com Contact: Investors Dina Vince Head of Investor Relations Delek Group Ltd. Tel: +972-9-863-8444 investor@delek-Group.com   Media Nilly Richman Head of Communications Delek Group Ltd. Tel : +972-9-863-8444 media@delek-Group.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delek-group-announces-consolidated-results-for-the-first-quarter-of-2017-300464997.html


Disaster recovery service provider Databarracks, has become a ‘Corporate Partner’ of the Business Continuity Institute (BCI), working with it to raise the profile of business continuity management (BCM) as a critical discipline for business resilience, amongst the SME community. Founded in 1994, the BCI has established itself as the leading organisation for BC professionals worldwide, supporting over 8,000 members in more than 100 countries and working with an estimated 3,000 organisations in private, public and third sectors. BCI members receive access to a wealth of resources and industry knowledge, centered around developing and maintaining professional competency in BC. A growing number of organisations are taking proactive steps to improve their business resilience. Evidence from this can be seen from Databarracks’ latest annual Data Health Check survey, which reveals that over the past eight years the volume of organisations adopting BC plans has increased from 37 per cent to 67 per cent. As a ‘Corporate Partner’, Databarracks will aim to help grow this figure further by working with the BCI to provide education and awareness of BCM best practice, notably amongst the SME community. Peter Groucutt, managing director of Databarracks commented: “The small and medium sized businesses in the UK that we work with will rarely have their own dedicated BC professionals. Our aim is to take the best-practice, expertise and knowledge and make it applicable and usable for our customers. Often we see the distinction between BC and IT disaster recovery (DR) are blurred for smaller businesses. We have been helping our customers with IT DR, but we want to go beyond IT to help improve overall business resilience. We are training all of our customer facing staff in the fundamentals of business continuity and now that we are a Corporate Partner of the BCI, we want to work with the institute to help raise the profile of BCM and improve resilience. David Thorp, Executive Director of the BCI added to this and welcomed Databarracks to the BCI: “It is a pleasure to welcome Databarracks as a Corporate Partner of the BCI and we look forward to working with them to help advance the industry. Databarracks bring a unique insight into the world of disaster recovery. Additionally, their drive and determination to help organisations become more secure and more resilient is a goal we both share. With our own Horizon Scan Report identifying just how great a threat the cyber landscape can pose to all organisations, it is essential that organisations work together to help combat this threat and improve resiliency.” About the Business Continuity Institute Founded in 1994 with the aim of promoting a more resilient world, the Business Continuity Institute (BCI) has established itself as the world’s leading Institute for business continuity and resilience. The BCI has become the membership and certifying organization of choice for business continuity and resilience professionals globally with over 8,000 members in more than 100 countries, working in an estimated 3,000 organizations in the private, public and third sectors. The vast experience of the Institute’s broad membership and partner network is built into its world class education, continuing professional development and networking activities. Every year, more than 1,500 people choose BCI training, with options ranging from short awareness raising tools to a full academic qualification, available online and in a classroom. The Institute stands for excellence in the resilience profession and its globally recognised Certified grades provide assurance of technical and professional competency. The BCI offers a wide range of resources for professionals seeking to raise their organization’s level of resilience, and its extensive thought leadership and research programme helps drive the industry forward. With approximately 120 Partners worldwide, the BCI Partnership offers organizations the opportunity to work with the BCI in promoting best practice in business continuity and resilience. For more information, please see: http://www.thebci.org About Databarracks: Databarracks provides ultra-secure, award winning Disaster Recovery, Backup and Infrastructure services from UK-based, ex-military data centres. Databarracks is certified by the Cloud Industry Forum, ISO 27001 certified for Information Security and has been named as a “Niche Player” in Gartner’s 2016 Magic Quadrant for DRaaS for the second year in a row. For more information, please see: http://www.databarracks.com


News Article | May 11, 2017
Site: www.prnewswire.com

The OTC 2017 featured a special procurement seminar on Ukraine organized by the U.S. Commercial Service in Ukraine, with support from Burisma Group. The event brought together representatives of Ukrainian and foreign oil & gas producers, embassies, NGOs and industry experts to address Ukraine's gas market future, business challenges and opportunities. Among key speakers at the seminar were the Senior Commercial Officer of the U.S. Commercial Service in Ukraine Jim Lindley, the Senior Oil and Gas Sector Specialist Myroslava Myrtsalo, the CEO of Ukrgazvydobuvannia Oleg Prokhorenko and the Advisor to the Board of Directors at Burisma Group Vadym Pozharskyi. In his address entitled 'Private gas production as a key to ensuring national energy security and independence', Vadym Pozharskyi, Advisor to the Board of the Burisma Group, focused on the need to boost Ukraine's domestic gas production. He talked about new ways to increase gas output, the importance of cooperation with the public sector and Burisma's state-of-the-art technology and oil and gas services. "Based on our 2017 corporate program, we will be investing circa UAH 3 billion in exploration and production. We are proud to produce billions of cubic meters of gas and contribute billions of hryvnias to the state budget of Ukraine. The huge advantage of the OTC for Ukraine is that it offers latest technologies allowing us to ramp up Ukraine's domestic gas production," Vadym Pozharskyi explained. The address also discussed how Ukraine offers an attractive investment environment and growth opportunities to oil and gas and service companies. It also recognised the effort and progress the country has made. In May, Burisma Group will be introducing the largest drilling rig in Ukraine. Vadym Pozharskyi extended an invitation to all participants of the OTC 2017 seminar on Ukraine to attend the event. For more detailed information please contact our press-centre: media@burisma.com Founded in 1969, the OTC is one of the key oil and gas industry events focused on offshore exploration, drilling and production. The NRG Park hosted over 2,300 companies from 100 countries that brought their projects and technologies. This year, the tradeshow attracted a record number of attendees - over 90,000 traders, managers, businessmen, engineers and scientists. The OTC is ranked among 200 largest tradeshows held annually in the United States and is among 10 largest gatherings in terms of attendance. Burisma Group is an independent oil and gas company operating in Ukraine. Since its launch in 2002, the Company has rapidly become one of the largest independent gas producers in the country. Burisma has been engaged in oil and gas exploration and production for more than 10 years. The core business is located in Ukraine, where the Group is the largest independent natural gas producer. Burisma is a market leader with annualized natural gas production circa 1,1 BCM and over 30% market share. Burisma is seeking for opportunities to expand its portfolio to other countries. Burisma has a state-of-the-art equipment and many years of experience to provide best services for oil and gas companies around the world. For more information, please visit http://burisma.com/en/


News Article | May 11, 2017
Site: www.prnewswire.co.uk

The OTC 2017 featured a special procurement seminar on Ukraine organized by the U.S. Commercial Service in Ukraine, with support from Burisma Group. The event brought together representatives of Ukrainian and foreign oil & gas producers, embassies, NGOs and industry experts to address Ukraine's gas market future, business challenges and opportunities. Among key speakers at the seminar were the Senior Commercial Officer of the U.S. Commercial Service in Ukraine Jim Lindley, the Senior Oil and Gas Sector Specialist Myroslava Myrtsalo, the CEO of Ukrgazvydobuvannia Oleg Prokhorenko and the Advisor to the Board of Directors at Burisma Group Vadym Pozharskyi. In his address entitled 'Private gas production as a key to ensuring national energy security and independence', Vadym Pozharskyi, Advisor to the Board of the Burisma Group, focused on the need to boost Ukraine's domestic gas production. He talked about new ways to increase gas output, the importance of cooperation with the public sector and Burisma's state-of-the-art technology and oil and gas services. "Based on our 2017 corporate program, we will be investing circa UAH 3 billion in exploration and production. We are proud to produce billions of cubic meters of gas and contribute billions of hryvnias to the state budget of Ukraine. The huge advantage of the OTC for Ukraine is that it offers latest technologies allowing us to ramp up Ukraine's domestic gas production," Vadym Pozharskyi explained. The address also discussed how Ukraine offers an attractive investment environment and growth opportunities to oil and gas and service companies. It also recognised the effort and progress the country has made. In May, Burisma Group will be introducing the largest drilling rig in Ukraine. Vadym Pozharskyi extended an invitation to all participants of the OTC 2017 seminar on Ukraine to attend the event. For more detailed information please contact our press-centre: media@burisma.com Founded in 1969, the OTC is one of the key oil and gas industry events focused on offshore exploration, drilling and production. The NRG Park hosted over 2,300 companies from 100 countries that brought their projects and technologies. This year, the tradeshow attracted a record number of attendees - over 90,000 traders, managers, businessmen, engineers and scientists. The OTC is ranked among 200 largest tradeshows held annually in the United States and is among 10 largest gatherings in terms of attendance. Burisma Group is an independent oil and gas company operating in Ukraine. Since its launch in 2002, the Company has rapidly become one of the largest independent gas producers in the country. Burisma has been engaged in oil and gas exploration and production for more than 10 years. The core business is located in Ukraine, where the Group is the largest independent natural gas producer. Burisma is a market leader with annualized natural gas production circa 1,1 BCM and over 30% market share. Burisma is seeking for opportunities to expand its portfolio to other countries. Burisma has a state-of-the-art equipment and many years of experience to provide best services for oil and gas companies around the world. For more information, please visit http://burisma.com/en/


News Article | March 1, 2017
Site: www.nature.com

The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. ARC-Net, University of Verona: approval number 1885 from the Integrated University Hospital Trust (AOUI) Ethics Committee (Comitato Etico Azienda Ospedaliera Universitaria Integrata) approved in their meeting of 17 November 2010, documented by the ethics committee 52070/CE on 22 November 2010 and formalized by the Health Director of the AOUI on the order of the General Manager with protocol 52438 on 23 November 2010. APGI: Sydney South West Area Health Service Human Research Ethics Committee, western zone (protocol number 2006/54); Sydney Local Health District Human Research Ethics Committee (X11-0220); Northern Sydney Central Coast Health Harbour Human Research Ethics Committee (0612-251M); Royal Adelaide Hospital Human Research Ethics Committee (091107a); Metro South Human Research Ethics Committee (09/QPAH/220); South Metropolitan Area Health Service Human Research Ethics Committee (09/324); Southern Adelaide Health Service/Flinders University Human Research Ethics Committee (167/10); Sydney West Area Health Service Human Research Ethics Committee (Westmead campus) (HREC2002/3/4.19); The University of Queensland Medical Research Ethics Committee (2009000745); Greenslopes Private Hospital Ethics Committee (09/34); North Shore Private Hospital Ethics Committee. Baylor College of Medicine: Institutional Review Board protocol numbers H-29198 (Baylor College of Medicine tissue resource), H-21332 (Genomes and Genetics at the BCM-HGSC), and H-32711(Cancer Specimen Biobanking and Genomics). Patients were recruited and consent obtained for genomic sequencing through the ARC-Net Research Centre at Verona University, Australian Pancreatic Cancer Genome Initiative (APGI), and Baylor College of Medicine as part of the ICGC (www.icgc.org). A patient criterion for admission to the study was that they were clinically sporadic. This information was acquired through direct interviews with participants and a questionnaire regarding their personal history and that of relatives with regard to pancreas cancers and any other cancers during anamnesis. Clinical records were also used to clarify familial history based on patient indications. Samples were prospectively and consecutively acquired through institutions affiliated with the Australian Pancreatic Cancer Genome Initiative. Samples from the ARC-Net biobank are the result of consecutive collections from a single centre. All tissue samples were processed as previously described5151. Representative sections were reviewed independently by at least one additional pathologist with specific expertise in pancreatic diseases. Samples either had full face frozen sectioning performed in optimal cutting temperature (OCT) medium, or the ends excised and processed in formalin to verify the presence of tumour in the sample to be sequenced and to estimate the percentage of neoplastic cells in the sample relative to stromal cells. Macrodissection was performed if required to excise areas that did not contain neoplastic epithelium. Tumour cellularity was determined using SNP arrays (Illumina) and the qpure tool9. PanNET is a rare tumour type and the samples were collected via an international network. We estimate that with 98 unique patients in the discovery cohort, we will achieve 90% power for 90% of genes to detect mutations that occur at a frequency of ~10% above the background rate for PanNET (assuming a somatic mutation frequency of more than 2 per Mb)52. Cancer and matched normal colonic mucosa were collected at the time of surgical resection from the Royal Brisbane and Women’s Hospital and snap frozen in liquid nitrogen. A biallelic germline mutation in the MUTYH gene was detected by restriction fragment length polymorphism analysis and confirmed by automated sequencing to be the G382D mutation (or ENST00000450313.5 G396D, ClinVar#5294) in both alleles53. The primary antibodies used for immunohistochemical staining were: cytokeratin 8/18 (5D3, Novocastra), chromogranin A (DAK-A3, Dako), and CD99 (O13, Biolegend). Antibodies and staining conditions have been described elsewhere39. Whole-genome sequencing with 100-bp paired reads was performed with a HiSEQ2000 (Illumina). Sequence data were mapped to a GRCh37 using BWA and BAM files are available in the EGA (accession number: EGAS00001001732). Somatic mutations and germline variants were detected using a previously described consensus mutation calling strategy11. Mutations were annotated with gene consequence using SNPeff. The pathogenicity of germline variants was predicted using cancer-specific and locus-specific genetic databases, medical literature, computational predictions with ENSEMBL Variant Effect Predictor (VEP) annotation, and second hits identified in the tumour genome. Intogen27 was used to find somatic genes that were significantly mutated. Somatic structural variants were identified using the qSV tool as previously described10, 11, 17. Coding mutations are included in supplementary tables and all mutations have been uploaded to the International Cancer Genome Consortium Data Coordination Center. Mutational signatures were predicted using a published framework14. Essentially, the 96-substitution classification was determined for each sample. The signatures were compared to other validated signatures and the prevalence of each signature per megabase was determined. Somatic copy number was estimated using high density SNP arrays and the GAP tool12. Arm level copy number data were clustered using Ward’s method, Euclidian distance. GISTIC13 was used to identify recurrent regions of copy number change. The whole genome sequence data was used to determine the length of the telomeres in each sample using the qMotif tool. Essentially, qMotif determines telomeric DNA content by calculating the number of reads that harbour the telomere motif (TTAGG), and then estimates the relative length of telomeres in the tumour compared to the normal. qMotif is available online (http://sourceforge.net/projects/adamajava). Telomere length was validated by qPCR as previously described54. RNASeq library preparation and sequencing were performed as previously described55. Essentially, sequencing reads were mapped to transcripts corresponding to ensemble 70 annotations using RSEM. RSEM data were normalized using TMM (weighted trimmed mean of M-values) as implemented in the R package ‘edgeR’. For downstream analyses, normalized RSEM data were converted to counts per million (c.p.m.) and log transformed. Genes without at least 1 c.p.m. in 20% of the sample were excluded from further analysis55. Unsupervised class discovery was performed using consensus clustering as implemented in the ConsensusClusterPlus R package56. The top 2,000 most variable genes were used as input. Differential gene expression analysis between representative samples was performed using the R package ‘edgeR’57. Ontology and pathway enrichment analysis was performed using the R package ‘dnet’58. PanNET class enrichment using published gene signatures44 was performed using Gene Set Variation Analysis (GSVA) as described previously55. Two strategies were used to verify fusion transcripts. For verification of EWSR1–BEND2 fusions, cDNAs were synthesized using the SuperScript VILO cDNA synthesis kit (Thermofisher) with 1 μg purified total RNA. For each fusion sequence, three samples were used: the PanNET sample containing the fusion, the PanNET sample without that fusion, and a non-neoplastic pancreatic sample. The RT–PCR product were evaluated on the Agilent 2100 Bioanalyzer (Agilent Technologies) and verified by sequencing using the 3130XL Genetic Analyzer (Life Technologies). Primers specific for EWSR1–BEND2 fusion genes are available upon request. To identify the EWSR1 fusion partner in the case ITNET_2045, a real-time RT–PCR translocation panel for detecting specific Ewing sarcoma fusion transcripts was applied as described59. Following identification of the fusion partner, PCR amplicons were subjected to sequencing using the 3130XL Genetic Analyzer. EWSR1 rearrangements were assayed on paraffin-embedded tissue sections using a commercial split-signal probe (Vysis LSI EWSR1 (22q12) Dual Colour, Break Apart Rearrangement FISH Probe Kit) that consists of a mixture of two FISH DNA probes. One probe (~500 kb) is labelled in SpectrumOrange and flanks the 5′ side of the EWSR1 gene, extending through intron 4, and the second probe (~1,100 kb) is labelled in SpectrumGreen and flanks the 3′ side of the EWSR1 gene, with a 7-kb gap between the two probes. With this setting, the assay enables the detection of rearrangements with breakpoints spanning introns 7–10 of the EWSR1 gene. Hybridization was performed according to the manufacturer’s instructions and scoring of tissue sections was assessed as described elsewhere60, counting at least 100 nuclei per slide. Recurrently mutated genes identified by whole-genome sequencing were independently evaluated in a series of 62 PaNETs from the ARC-Net Research Centre, University of Verona. Four Ion Ampliseq Custom panels (Thermofisher) were designed to target the entire coding regions and flanking intron–exon junctions of the following genes: MEN1, DAXX, ATRX, PTEN and TSC2 (panel 1); DEPDC5, TSC1 and SETD2 (panel 2); ARID1A and MTOR (panel 3); CHEK2 and MUTYH (panel 4). Twenty nanograms of DNA were used per multiplex PCR amplification. The quality of the obtained libraries was evaluated by the Agilent 2100 Bioanalyzer on chip electrophoresis. Emulsion PCR was performed with the OneTouch system (Thermofisher). Sequencing was run on the Ion Torrent Personal Genome Machine (PGM, Thermofisher) loaded with 316 or 318 chips. Data analysis, including alignment to the hg19 human reference genome and variant calling, was done using Torrent Suite Software v4.0 (Thermofisher). Filtered variants were annotated using a custom pipeline based on the Variant Effector Predictor (VEP) software. Alignments were visually verified with the Integrative Genomics Viewer: IGV v2.3 (Broad Institute). There is no contiguous structure available for CHEK2, so we produced a model of isoform C using PDBid 3i6w61 as a template for predicting the structure of sequence O96017. Modelling was carried out within the YASARA suite of programs62 and consisted of an initial BLAST search for suitable templates followed by alignment, building of loops not present in selected template structure and energy minimization in explicit solvent. Modelling was carried out in the absence of a phosphopeptide ligand, which was added on completion by aligning the model with structure 1GXC and merging the ligand contained therein with the model structure. Similarly, MUTYH is represented by discontinuous structures and so this too was modelled using PDBids 3N5N and 4YPR as templates together with sequence NP_036354.1. Having constructed both models, amino acid substitutions were carried out to make the wild-type sequences conform to the variants described above. Each substitution was carried out independently and the resulting variant structures were subject to simulated annealing energy minimization using the AMBER force field. The resulting energy-minimized structures formed the basis of the predictions. CHEK2 site mutants were generated by site-directed mutagenesis of wild-type pCMV–FLAG CHEK2 (primer sequences in Supplementary Table 16). Proteins were expressed in HEK293T, a highly transfectable derivative of HEK293 cells that were retrieved from the cell culture bank at the QIMR Berghofer medical research institute. Cells were authenticated by STR profiling and were negative for mycoplasma. Transfected cells were lysed in NP-40 modified RIPA with protease and phosphatase inhibitors. Protein expression levels were analysed by western blotting with anti-FLAG antibodies and imaging HRP luminescent signal on a CCD camera (Fuji) and quantifying in MultiGauge software (Fuji). Kinase assays were performed using recombinant GST–CDC25C (amino acids 200–256) as substrate, essentially as described63. Kinase assay quantification was performed by scintillation counting of excised gel bands in OptiPhase scintillant (Perkin Elmer) using a Tri-Carb 2100TR beta counter (Packard). Counts for each reaction set were expressed as a fraction of the wild type. All experiments were performed at least three times. The date of diagnosis and the date and cause of death for each patient were obtained from the Central Cancer Registry and treating clinicians. Median survival was estimated using the Kaplan–Meier method and the difference was tested using the log-rank test. P values of less than 0.05 were considered statistically significant. The hazard ratio and its 95% confidence interval were estimated using Cox proportional hazard regression modelling. The correlation between DAXX or ATRX mutational status and other clinico-pathological variables was calculated using the χ2 test. Statistical analysis was performed using StatView 5.0 Software (Abacus Systems). Disease-specific survival was used as the primary endpoint. Genome sequencing data presented in this study have been submitted to the European Genome-Phenome Archive under accession number EGAS00001001732 (https://www.ebi.ac.uk/ega/search/site/EGAS00001001732).


News Article | February 24, 2017
Site: www.eurekalert.org

The genetic material of an organism encodes the instructions that guide its development. These codes are not written in stone; they can change or mutate any time during the life of the organism. Single changes in the code can occur spontaneously, as a mutation, causing developmental problems. Others, as an international team of researchers has discovered, are too numerous to be explained by random mutation processes present in the general population. When such multiple genetic changes occur before or early after conception, they may inform scientists about fundamental knowledge underlying many diseases. The study appears in Cell. "As a part of the clinical evaluation of young patients with a variety of developmental issues, we performed clinical genomic studies and analyzed the genetic material of more than 60,000 individuals. Most of the samples were analyzed at Baylor Genetics laboratories," said lead author Dr. Pengfei Liu, assistant professor of molecular and human genetics Baylor College of Medicine and assistant laboratory director of Baylor Genetics. "Of these samples, five had extreme numbers of genetic changes that could not be explained by random events alone." The researchers looked at a type of genetic change called copy number variants, which refers to the number of copies of genes in human DNA. Normally we each have two copies of each gene located on a pair of homologous chromosomes. "Copy number variants in human DNA can be compared to repeated or missing paragraphs or pages of text in a book," said senior author Dr. James R. Lupski, Cullen Professor of Molecular and Human Genetics at Baylor. "For instance, if one or two pages are duplicated in a book it could be explained by random mistakes. On the other hand, if 10 different pages are duplicated, you have to suspect that it did not happen by chance. We want to understand the basic mechanism underlying these multiple new copy number variant mutations in the human genome." A rare, early and transitory phenomenon that can affect human development The researchers call this phenomenon multiple de novo copy number variants. As the name indicates, the copy number variants are many and new (de novo). The latter means that the patients carrying the genetic changes did not inherit them from their parents because neither the mother nor the father carries the changes. In this rare phenomenon, the copy number variants are predominantly gains - duplications and triplications - rather than losses of genetic material, and are present in all the cells of the child. The last piece of evidence together with the fact that the parents do not carry the alterations suggest that the extra copies of genes may have occurred either in the sperm or the egg, the parent's germ cells, and before or very early after fertilization. "This burst of genetic changes happens only during the early stages of embryonic development and then it stops," Liu said. "Interestingly, despite having a large number of mutations, the young patients present with relatively mild neurological problems." The researchers are analyzing more patient samples looking for additional cases of multiple copy number variants to continue their investigation of what may trigger this rare phenomenon. "We hope that as more researchers around the world learn about this and confirm it, the number of cases will increase," Liu said. "This will improve our understanding of the underlying mechanism and of why and how pathogenic copy number variants arise not only in developmental disorders but in cancers." "A new era of clinical genomics-supported medicine and research" This discovery has been possible in great measure thanks to the breadth of genetic testing performed and genomic data available at Baylor Genetics laboratory. "The diagnostics lab Baylor Genetics is one of the pioneers in this new era of clinical genomics-supported medical practice and disease gene discovery research," Lupski said. "They are developing the clinical genomics necessary to foster and support the Precision Medicine Initiative of the National Institutes of Health, and generating the genomics data that further drives human genome research." Using state-of-the art technologies and highly-trained personnel, Baylor Genetics analyzes hundreds of samples daily for genetic evaluation of patients with conditions suspected to have underlying genetic factors potentially contributing to their disease. Having this wealth of information and insight into the genetic mechanisms of disease offers now the possibility of advancing medicine and basic research in ways that were not available before. "There is so much that both clinicians and researchers can learn from the data generated in diagnostic labs," Liu said. "Clinicians receive genomic information that can aid in diagnosis and treatment of their patients, and researchers gather data that can help them unveil the mechanisms underlying the biological perturbations resulting in the patients' conditions." Other contributors to this work include Bo Yuan, Claudia M.B. Carvalho, Arthur Wuster, Klaudia Walter, Ling Zhang, Tomasz Gambin, Zechen Chong, Ian M. Campbell, Zeynep Coban Akdemir, Violet Gelowani, Karin Writzl, Carlos A. Bacino, Sarah J. Lindsay, Marjorie Withers, Claudia Gonzaga-Jauregui, Joanna Wiszniewska, Jennifer Scull, Pawel Stankiewicz, Shalini N. Jhangiani, Donna M. Muzny, Feng Zhang, Ken Chen, Richard A. Gibbs, Bernd Rautenstrauss, Sau Wai Cheung, Janice Smith, Amy Breman, Chad A. Shaw, Ankita Patel and Matthew E. Hurles. The researchers are affiliated with one of more of the following institutions Baylor, Wellcome Trust Sanger Institute in the U.K., Fudan University in China, the University of Texas MD Anderson Cancer Center Houston, the Clinical Institute of Medical Genetics in Slovenia and the Medical Genetics Center in Germany. This work was supported in part by grants from the US National Institute of Neurological Disorders and Stroke (R01NS058529), the National Human Genome Research Institute (U54HG003273), a joint NHGRI/National Heart Blood and Lung Institute grant (U54HG006542) to the Baylor Hopkins Center for Mendelian Genomics, and the BCM Intellectual and Developmental Disabilities Research Center, IDDRC Grant Number 5P30HD024064-23, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The work was also partially supported by the Wellcome Trust (WT098051).


News Article | March 2, 2017
Site: www.prnewswire.co.uk

Burisma Group, Ukraine's largest independent gas company, has announced on Tuesday at the Ukrainian Energy Forum a $100m USD investment to develop gas projects in Ukraine, a major step in helping Ukraine achieve energy independence. Burisma Group announced its 2017 corporate "billion" program according to which the Group is going to reach over 1 bcm of gas production levels, increase investments in development of gas fields, drill and bring into operation new wells worth more than UAH 3 billion ($100m USD) and pay 2 billion UAH of taxes to the budgets of all levels. At the same time, over the last two years alone, Burisma Group paid around UAH 6 billion to the State budget of Ukraine. Thanks to the investment program, the Group is going to drill 20 new wells where 3 out of every 4 would be more than 5000 m deep and have complex profiles. Burisma Group is the headliner at this week's Ukrainian Energy Forum, Ukraine's largest annual energy conference organized by Adam Smith Conferences. Since 1992, Adam Smith Conferences have been organizing highly professional economic forums that bring together thousands of state and business leaders in Ukraine. The topic of the VIII Ukrainian Energy Forum is "Raising domestic output, diversity and security of supply through reform, transparency and modernization". Key Forum speakers include the Vice Prime Minister of Ukraine Volodymyr Kistion, the Minister of Ecology and Natural Resources of Ukraine Ostap Semerak, the acting Head of the Committee on Fuel and Energy Complex, Nuclear Policy and Nuclear Security of the Verkhovna Rada Alexander Dombrovskyi, Advisor to the Board of Directors and Director for International Cooperation and Strategic Development of Burisma Group Vadym Pozharskyi, the Director of the Energy Community Secretariat Janez Kopač and others. "It is symbolic that Burisma led the discussions on energy efficiency and supported the State's new policy of reforming the national energy market, as well as promoting Ukraine's European integration. Burisma Group has always encouraged government and market players to reform the Ukrainian gas market based on European best practices. It is crucial that market players, infrastructure investors and Ukraine's international partners see our country as a reliable partner. Burisma is committed to ensuring Ukraine's energy security", noted Vadym Pozharskyi. According to the Vice Prime Minister of Ukraine Volodymyr Kistion, today it is of major importance for Ukraine to be an energy independent country. The Forum participants also focused on diversification of energy sources. Janez Kopač called for the further improvement of legal framework regulating the Ukrainian energy market. In his speech, Vadym Pozharskyi shared success stories of cooperation between government and businesses in other countries on the implementation of an energy independence strategy. "The energy sector remains a key source of revenues for the Ukrainian budget. Gas companies not only provide the country with domestic gas, but also continue to invest billions in production and introduce state-of-the-art exploration and drilling technologies. We are going to stay committed to this strategy", noted Vadym Pozharskyi. Burisma Group is an independent oil and gas company operating in Ukraine. Since its launch in 2002, the Company has rapidly become one of the largest independent gas producers in the country. Burisma has been engaged in oil and gas exploration and production for more than 10 years. The core business is located in Ukraine, where the Group is the largest independent natural gas producer. Burisma is a market leader with annualized natural gas production circa 1,1 BCM and over 30% market share. Burisma is seeking for opportunities to expand its portfolio to other countries. Burisma has a state-of-the-art equipment and many years of experience to provide best services for oil and gas companies around the world. For more information, please visit http://burisma.com/en/


News Article | February 17, 2017
Site: www.prnewswire.com

VANCOUVER, Feb. 16, 2017 /PRNewswire/ - Bear Creek Mining (TSX Venture: "BCM") ("Bear Creek" or the "Company") announces that its Board of Directors has authorized and approved the grant of 1,050,500 incentive stock options under its incentive stock option plan (the "Stock Option Plan")...


News Article | March 2, 2017
Site: www.prnewswire.co.uk

TOKYO, March 2, 2017 /PRNewswire/ -- Sungrow, the world's leading PV inverter manufacturer, launched a new product for Japan's solar market with the reveal of its new string inverter, the SG33K3J, at the 7th Annual Int'l Smart Grid Expo in Tokyo. (Booth W10-20, Tokyo Big Sight, Mar. 1-3) As an important supplement to the string inverter pipeline led by the SG49K5J, Sungrow's flagship product in Japan, the SG33K3J expands possibilities for solar customers. The SG33K3J and the SG49K5J are both designed for higher power generation with DC/AC ratio of the SG33K3J reaching up to 2.0. Central inverters were also featured at the Tokyo show. Sungrow showcased the SG2000, recently employed in the BCM's (Blue Capital Management Co., Ltd) 200MW power plant. "Sungrow is committed to technical innovation. We continue to bring new products and solutions to better meet ever-changing demands from customers in Japan," said Renxian Cao, president of Sungrow. Sungrow is the world's leading PV-inverter manufacturer with over 26GW (up to June 2016) installed globally. Founded in 1997 by the University Professor Renxian Cao, Sungrow is the global leader in research and development in solar inverters, with numerous patents and a broad product portfolio offering solutions for residential, commercial and industrial applications. With a 20-year track record of growth and success, Sungrow's products are available in over 50 countries, and have maintained a market share of over 30% in China. In 2015, Sungrow successfully occupied an over 20% market share in Germany. Sungrow topped the world with PV inverter shipments of 2015 reaching up to 8.9GW. Learn more about Sungrow by visiting: http://www.sungrowpower.com

Loading BCM collaborators
Loading BCM collaborators